FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Draft Guide on Human Factors Subsmissions

[ Price : $8.95]

FDA issues a draft guidance entitled Contents of a Complete Submission for Threshold Analyses and Human Factors Submissions to Dru...

FDA Reclassifies Single-use Female Condoms

[ Price : $8.95]

Federal Register notice: FDA issues a final order to reclassify single- use female condoms, renaming the device to single-use inte...

FDA Draft Guides on Adaptive Trials and Master Protocols

[ Price : $8.95]

FDA issues two new draft guidance documents one on adaptive clinical trial designs and the other on master protocols that propos...

Pfizers Vizimpro Approved for Lung Cancer

[ Price : $8.95]

FDA approves Pfizers Vizimpro (dacomitinib), a kinase inhibitor for the first-line treatment of certain patients with metastatic n...

Sens. Hatch, Bennet Bill on Updating Drug Labels

[ Price : $8.95]

Senators Orrin Hatch (R-UT) and Michael Bennet (D-CO) introduce Making Objective Drug Evidence Revisions for New(MODERN) Labeling ...

FDA Clears Next Gen Sequencing Assay

[ Price : $8.95]

FDA clears a de novo request to permit the marketing of Adaptive Biotechnologies ClonoSEQ assay, a next-generation sequencing-base...

Guide on Outsourcing Facility Adverse Event Reporting

[ Price : $8.95]

FDA releases a final guidance entitled Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, ...

FDA Asks Labeling Change for Pen Needles

[ Price : $8.95]

FDA asks pen needle manufacturers to add a label Warning regarding proper use of the devices.

Sun Pharmaceutical FDA-483

[ Price : $8.95]

FDA releases the FDA-483 with two observations from a September inspection at the Sun Pharmaceutical facility in Punjab, India.

Strides Pharma FDA-483

[ Price : $8.95]

FDA releases the FDA-483 with three observations from an inspection at Indias Stride Pharma Science.